The document aims to clarify regulation rules of minimal manipulation with human cell and tissue products. The FDA’s guidance documents normally do not “establish legally enforceable responsibilities” but “describe the agency’s current thinking on a topic and should be viewed only as recommendations,” the agency said.
HCT/Ps are “intended for implantation, transplantation, infusion or transfer into a human recipient,” according to the FDA’s definition. The agency clarified that hospitals and labs do not have to register human cell and tissue-based products “that are used solely for nonclinical scientific or educational purposes.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
